The GPCR field is experiencing a renaissance, driven by renewed investment, clinical progress, and next-generation technologies unlocking hundreds of previously untargeted receptors. Furthermore, we’ve recently seen Takeda and Iambic Therapeutics’ $1.7bn partnership to advance AI-driven small molecule programs, and Kainova Therapeutics securing $32m CAD to accelerate immuno-oncology and inflammation therapies, momentum in the GPCR space continues to build. The race is on to validate new GPCRs, understand dynamic activation mechanisms, and develop assays that better predict therapeutic efficacy and guide smarter candidate selection.

Returning as the only industry-led meeting dedicated to GPCR drug discovery, the 5th GPCR-Targeted Drug Discovery Summit features a jam-packed agenda with:

• 12+ companies unveiling never seen before data
• 12+ C-Level speakers
• 9+ presentations on non-small molecule GPCR-targeting drug discovery

This is the place to learn about the latest targets, tools, and therapeutic strategies. Join 80+ GPCR-focused leaders across biopharma to share insights, build collaborations, and accelerate next-generation therapeutics from discovery to clinic.

To know more visit: https://ter.li/etb3m3